SK285325B6 - Membrána alebo matrica na riadenie rýchlosti permeácie liekov, ktorá obsahuje elastomérnu kompozíciu na báze siloxánu, obsahujúca aspoň jeden elastomér a prípadne nezosieťovaný polymér a spôsob prípravy elastoméru - Google Patents

Membrána alebo matrica na riadenie rýchlosti permeácie liekov, ktorá obsahuje elastomérnu kompozíciu na báze siloxánu, obsahujúca aspoň jeden elastomér a prípadne nezosieťovaný polymér a spôsob prípravy elastoméru Download PDF

Info

Publication number: SK285325B6
Authority: SK; Slovakia
Prior art keywords: groups; poly; elastomer; lower alkyl; sir
Prior art date: 1998-06-30

Application number

SK1894-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK18942000A3 (sk

Inventor

Harri Jukarainen

Tommi Makkula

Juha Ala-Sorvari

Matti Lehtinen

Jarkko Ruohonen

Original Assignee

Schering Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-30

Filing date

1999-06-11

Publication date

2006-11-03

1999-06-11 Application filed by Schering Oy filed Critical Schering Oy

2001-07-10 Publication of SK18942000A3 publication Critical patent/SK18942000A3/sk

2006-11-03 Publication of SK285325B6 publication Critical patent/SK285325B6/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 136
229920001971 elastomer Polymers 0.000 title claims abstract description 69
239000000806 elastomer Substances 0.000 title claims abstract description 69
239000012528 membrane Substances 0.000 title claims abstract description 64
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 title claims abstract description 38
239000003814 drug Substances 0.000 title claims abstract description 24
239000011159 matrix material Substances 0.000 title claims abstract description 24
238000000034 method Methods 0.000 title claims abstract description 10
229920006037 cross link polymer Polymers 0.000 title claims abstract description 4
229940079593 drug Drugs 0.000 title description 19
-1 polysiloxane units Polymers 0.000 claims abstract description 57
229920000233 poly(alkylene oxides) Polymers 0.000 claims abstract description 45
229920000642 polymer Polymers 0.000 claims abstract description 34
238000002360 preparation method Methods 0.000 claims abstract description 6
125000000217 alkyl group Chemical group 0.000 claims description 51
239000003054 catalyst Substances 0.000 claims description 49
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 43
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 37
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 32
229920001577 copolymer Polymers 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 29
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
239000001257 hydrogen Substances 0.000 claims description 27
239000000945 filler Substances 0.000 claims description 23
150000004678 hydrides Chemical class 0.000 claims description 22
229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 19
229920002554 vinyl polymer Chemical group 0.000 claims description 19
239000000377 silicon dioxide Substances 0.000 claims description 16
229920001400 block copolymer Polymers 0.000 claims description 15
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
229920001296 polysiloxane Polymers 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 10
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 9
101150065749 Churc1 gene Proteins 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
102100038239 Protein Churchill Human genes 0.000 claims description 9
150000002978 peroxides Chemical class 0.000 claims description 7
125000002947 alkylene group Chemical group 0.000 claims description 6
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
150000002431 hydrogen Chemical group 0.000 claims description 5
125000001424 substituent group Chemical group 0.000 claims description 4
229920001002 functional polymer Polymers 0.000 claims description 3
150000001336 alkenes Chemical class 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
239000003431 cross linking reagent Substances 0.000 description 40
239000003112 inhibitor Substances 0.000 description 38
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 37
229920000974 Poly(dimethylsiloxane-ethylene oxide) Polymers 0.000 description 30
239000002202 Polyethylene glycol Substances 0.000 description 25
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
238000004132 cross linking Methods 0.000 description 23
229910052697 platinum Inorganic materials 0.000 description 20
239000011541 reaction mixture Substances 0.000 description 17
239000004615 ingredient Substances 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 10
229960000834 vinyl ether Drugs 0.000 description 9
229920005601 base polymer Polymers 0.000 description 7
UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 7
238000007731 hot pressing Methods 0.000 description 6
238000002156 mixing Methods 0.000 description 6
238000006116 polymerization reaction Methods 0.000 description 6
238000004821 distillation Methods 0.000 description 5
229920000578 graft copolymer Polymers 0.000 description 5
238000012360 testing method Methods 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
230000009849 deactivation Effects 0.000 description 4
230000008034 disappearance Effects 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000000376 reactant Substances 0.000 description 4
BOOBDAVNHSOIDB-UHFFFAOYSA-N (2,3-dichlorobenzoyl) 2,3-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC=CC(C(=O)OOC(=O)C=2C(=C(Cl)C=CC=2)Cl)=C1Cl BOOBDAVNHSOIDB-UHFFFAOYSA-N 0.000 description 3
WRXCBRHBHGNNQA-UHFFFAOYSA-N (2,4-dichlorobenzoyl) 2,4-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC(Cl)=CC=C1C(=O)OOC(=O)C1=CC=C(Cl)C=C1Cl WRXCBRHBHGNNQA-UHFFFAOYSA-N 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
231100000508 hormonal effect Toxicity 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229920002959 polymer blend Polymers 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
238000003756 stirring Methods 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
238000007259 addition reaction Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000008096 xylene Substances 0.000 description 2
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
QYLFHLNFIHBCPR-UHFFFAOYSA-N 1-ethynylcyclohexan-1-ol Chemical compound C#CC1(O)CCCCC1 QYLFHLNFIHBCPR-UHFFFAOYSA-N 0.000 description 1
VMAWODUEPLAHOE-UHFFFAOYSA-N 2,4,6,8-tetrakis(ethenyl)-2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane Chemical compound C=C[Si]1(C)O[Si](C)(C=C)O[Si](C)(C=C)O[Si](C)(C=C)O1 VMAWODUEPLAHOE-UHFFFAOYSA-N 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000004594 Masterbatch (MB) Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
HMDDXIMCDZRSNE-UHFFFAOYSA-N [C].[Si] Chemical group [C].[Si] HMDDXIMCDZRSNE-UHFFFAOYSA-N 0.000 description 1
125000005011 alkyl ether group Chemical group 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000000708 anti-progestin effect Effects 0.000 description 1
239000003418 antiprogestin Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
FSIJKGMIQTVTNP-UHFFFAOYSA-N bis(ethenyl)-methyl-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C=C)C=C FSIJKGMIQTVTNP-UHFFFAOYSA-N 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000005331 crown glasses (windows) Substances 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
VOXZDWNPVJITMN-WKUFJEKOSA-N estradiol group Chemical class [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960004400 levonorgestrel Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229920006030 multiblock copolymer Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000010703 silicon Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229940126703 systemic medication Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/10—Block- or graft-copolymers containing polysiloxane sequences
- C08L83/12—Block- or graft-copolymers containing polysiloxane sequences containing polyether sequences
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Polymers & Plastics (AREA)
Silicon Polymers (AREA)
Compositions Of Macromolecular Compounds (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)
Wrappers (AREA)
Manufacture Of Macromolecular Shaped Articles (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Separation Using Semi-Permeable Membranes (AREA)

SK1894-2000A 1998-06-30 1999-06-11 Membrána alebo matrica na riadenie rýchlosti permeácie liekov, ktorá obsahuje elastomérnu kompozíciu na báze siloxánu, obsahujúca aspoň jeden elastomér a prípadne nezosieťovaný polymér a spôsob prípravy elastoméru SK285325B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FI981506A FI107339B (fi)	1998-06-30	1998-06-30	Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
PCT/FI1999/000511 WO2000000550A1 (fr)	1998-06-30	1999-06-11	Membrane ou matrice permettant de reguler la vitesse de permeation des medicaments

Publications (2)

Publication Number	Publication Date
SK18942000A3 SK18942000A3 (sk)	2001-07-10
SK285325B6 true SK285325B6 (sk)	2006-11-03

Family

ID=8552104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1894-2000A SK285325B6 (sk)	1998-06-30	1999-06-11	Membrána alebo matrica na riadenie rýchlosti permeácie liekov, ktorá obsahuje elastomérnu kompozíciu na báze siloxánu, obsahujúca aspoň jeden elastomér a prípadne nezosieťovaný polymér a spôsob prípravy elastoméru

Country Status (28)

Country	Link
EP (1)	EP1124902B1 (fr)
JP (1)	JP2002519467A (fr)
KR (1)	KR100599868B1 (fr)
CN (2)	CN1176999C (fr)
AR (1)	AR018952A1 (fr)
AT (1)	ATE290049T1 (fr)
AU (1)	AU752895B2 (fr)
BG (1)	BG65148B1 (fr)
BR (1)	BR9911140B1 (fr)
CA (1)	CA2336149C (fr)
CO (1)	CO5060523A1 (fr)
CZ (1)	CZ299613B6 (fr)
DE (1)	DE69923992T2 (fr)
EE (1)	EE04685B1 (fr)
ES (1)	ES2237120T3 (fr)
FI (1)	FI107339B (fr)
HU (1)	HU229159B1 (fr)
NO (1)	NO327955B1 (fr)
NZ (1)	NZ508275A (fr)
PE (1)	PE20000935A1 (fr)
PL (1)	PL193485B1 (fr)
PT (1)	PT1124902E (fr)
RU (1)	RU2201794C2 (fr)
SK (1)	SK285325B6 (fr)
TW (1)	TWI237571B (fr)
UA (1)	UA71566C2 (fr)
WO (1)	WO2000000550A1 (fr)
ZA (1)	ZA200006986B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6476079B1 (en) *	1999-12-23	2002-11-05	Leiras Oy	Devices for the delivery of drugs having antiprogestinic properties
AU2002210580A1 (en) *	2000-10-20	2002-04-29	Leiras Oy	Drug delivery system
EP1438942A1 (fr)	2003-01-17	2004-07-21	Schering Oy	Dispositif d'administration de médicament otologique et rhinologique
WO2006026040A1 (fr) *	2004-08-25	2006-03-09	Union Carbide Chemicals & Plastics Technology Corporation	Film polymere
US7862552B2 (en)	2005-05-09	2011-01-04	Boston Scientific Scimed, Inc.	Medical devices for treating urological and uterine conditions
CA2675585C (fr)	2007-03-12	2015-10-06	Bayer Schering Pharma Oy	Utilisation du tocopherol comme co-catalyseur dans la polymerisation parouverture de chaine de siloxanes cycliques
EP2140860A1 (fr)	2008-07-03	2010-01-06	Bayer Schering Pharma Oy	Procédé de contraception amélioré
US20110166508A1 (en)	2008-09-17	2011-07-07	Lyytikaeinen Heikki	inserter
FI20080524A0 (fi)	2008-09-17	2008-09-17	Bayer Schering Pharma Oy	Insertteri
FI20080523A0 (fi)	2008-09-17	2008-09-17	Bayer Schering Pharma Oy	Insertteri
US11992431B2 (en)	2008-09-17	2024-05-28	Bayer Oy	Inserter
FI122579B (fi)	2010-10-29	2012-03-30	Bayer Oy	Insertteri
CN102008909B (zh) *	2010-12-13	2012-10-10	大连欧科膜技术工程有限公司	一种气体分离复合膜的制备方法
CN102068914B (zh) *	2010-12-13	2012-10-10	大连欧科膜技术工程有限公司	一种气体分离复合膜的制备方法
TW201350122A (zh)	2012-04-23	2013-12-16	Bayer Pharma AG	１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
PE20142437A1 (es)	2012-04-23	2015-01-31	Bayer Pharma AG	Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino
TN2016000134A1 (en) *	2013-10-18	2017-10-06	Bayer Oy	Intrauterine delivery system.
CN108135910B (zh)	2015-05-13	2022-12-02	拜耳股份有限公司	长效药物递送装置及其在避孕中的用途
WO2018202574A1 (fr)	2017-05-04	2018-11-08	Bayer Oy	Système d'administration de médicament intravaginal, procédé de fabrication d'un tel système et son utilisation dans des thérapies gynécologiques et en contraception
WO2019119059A1 (fr)	2017-12-22	2019-06-27	Alyra Biotech Pty Ltd	Traitement de la douleur et/ou des symptômes liés à la douleur associés à la dysménorrhée
ES2834450T3 (es) *	2018-03-05	2021-06-17	Evonik Operations Gmbh	Copolímeros en bloques de poliéter-siloxano reticulados, así como su empleo para la producción de espumas de poliuretano
US20220233469A1 (en)	2019-05-31	2022-07-28	Alyra Biotech Pty Ltd	Methods, compositions and devices for treating neuroinflammatory conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5889108A (en) *	1997-06-02	1999-03-30	Dow Corning Corporation	Thickening solvents with elastomeric silicone polyethers

1998
- 1998-06-30 FI FI981506A patent/FI107339B/fi not_active IP Right Cessation
1999
- 1999-06-04 TW TW088109291A patent/TWI237571B/zh not_active IP Right Cessation
- 1999-06-08 CO CO99035747A patent/CO5060523A1/es unknown
- 1999-06-11 WO PCT/FI1999/000511 patent/WO2000000550A1/fr not_active Ceased
- 1999-06-11 EE EEP200000788A patent/EE04685B1/xx not_active IP Right Cessation
- 1999-06-11 PL PL99345103A patent/PL193485B1/pl unknown
- 1999-06-11 KR KR1020007015121A patent/KR100599868B1/ko not_active Expired - Fee Related
- 1999-06-11 NZ NZ508275A patent/NZ508275A/xx not_active IP Right Cessation
- 1999-06-11 EP EP99931285A patent/EP1124902B1/fr not_active Expired - Lifetime
- 1999-06-11 ES ES99931285T patent/ES2237120T3/es not_active Expired - Lifetime
- 1999-06-11 PT PT99931285T patent/PT1124902E/pt unknown
- 1999-06-11 JP JP2000557307A patent/JP2002519467A/ja active Pending
- 1999-06-11 DE DE69923992T patent/DE69923992T2/de not_active Expired - Lifetime
- 1999-06-11 CA CA002336149A patent/CA2336149C/fr not_active Expired - Fee Related
- 1999-06-11 AU AU47839/99A patent/AU752895B2/en not_active Ceased
- 1999-06-11 SK SK1894-2000A patent/SK285325B6/sk not_active IP Right Cessation
- 1999-06-11 HU HU0102600A patent/HU229159B1/hu not_active IP Right Cessation
- 1999-06-11 RU RU2001102606/04A patent/RU2201794C2/ru not_active IP Right Cessation
- 1999-06-11 CN CNB998081388A patent/CN1176999C/zh not_active Expired - Fee Related
- 1999-06-11 CZ CZ20004749A patent/CZ299613B6/cs not_active IP Right Cessation
- 1999-06-11 BR BRPI9911140-3A patent/BR9911140B1/pt not_active IP Right Cessation
- 1999-06-11 CN CNB031429661A patent/CN1269909C/zh not_active Expired - Fee Related
- 1999-06-11 AT AT99931285T patent/ATE290049T1/de active
- 1999-06-25 PE PE1999000584A patent/PE20000935A1/es not_active Application Discontinuation
- 1999-06-25 AR ARP990103082A patent/AR018952A1/es active IP Right Grant
- 1999-11-06 UA UA2001010652A patent/UA71566C2/uk unknown
2000
- 2000-11-28 ZA ZA200006986A patent/ZA200006986B/en unknown
- 2000-12-21 BG BG105081A patent/BG65148B1/bg unknown
- 2000-12-21 NO NO20006581A patent/NO327955B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO20006581L (no)	2000-12-29
FI981506A0 (fi)	1998-06-30
EP1124902B1 (fr)	2005-03-02
ATE290049T1 (de)	2005-03-15
PE20000935A1 (es)	2000-09-18
ES2237120T3 (es)	2005-07-16
ZA200006986B (en)	2001-05-23
UA71566C2 (uk)	2004-12-15
BR9911140B1 (pt)	2009-08-11
HU229159B1 (hu)	2013-09-30
WO2000000550A1 (fr)	2000-01-06
NZ508275A (en)	2002-09-27
BG65148B1 (bg)	2007-04-30
KR100599868B1 (ko)	2006-07-12
DE69923992T2 (de)	2006-04-13
AU752895B2 (en)	2002-10-03
FI981506L (fi)	1999-12-31
NO20006581D0 (no)	2000-12-21
CA2336149A1 (fr)	2000-01-06
KR20010053346A (ko)	2001-06-25
CZ20004749A3 (cs)	2001-10-17
SK18942000A3 (sk)	2001-07-10
AR018952A1 (es)	2001-12-12
EE04685B1 (et)	2006-08-15
CN1488678A (zh)	2004-04-14
CO5060523A1 (es)	2001-07-30
DE69923992D1 (de)	2005-04-07
PL193485B1 (pl)	2007-02-28
PT1124902E (pt)	2005-07-29
NO327955B1 (no)	2009-10-26
FI107339B (fi)	2001-07-13
RU2201794C2 (ru)	2003-04-10
CA2336149C (fr)	2007-01-02
CN1176999C (zh)	2004-11-24
HUP0102600A3 (en)	2004-04-28
TWI237571B (en)	2005-08-11
HK1038939A1 (en)	2002-04-04
HUP0102600A2 (hu)	2001-11-28
EP1124902A1 (fr)	2001-08-22
PL345103A1 (en)	2001-12-03
AU4783999A (en)	2000-01-17
EE200000788A (et)	2002-04-15
CN1269909C (zh)	2006-08-16
BG105081A (en)	2001-09-28
BR9911140A (pt)	2001-03-06
CN1308653A (zh)	2001-08-15
JP2002519467A (ja)	2002-07-02
CZ299613B6 (cs)	2008-09-17

Legal Events

Date	Code	Title	Description
2016-03-01	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20150611

Publication	Publication Date	Title
SK285325B6 (sk)	2006-11-03	Membrána alebo matrica na riadenie rýchlosti permeácie liekov, ktorá obsahuje elastomérnu kompozíciu na báze siloxánu, obsahujúca aspoň jeden elastomér a prípadne nezosieťovaný polymér a spôsob prípravy elastoméru
KR100850548B1 (ko)	2008-08-06	항프로게스테론 특성을 가지는 약물의 전달 장치
CN1127535C (zh)	2003-11-12	控制药物渗透的方法
US5597584A (en)	1997-01-28	Method of controlling release of an active or drug from a silicone rubber matrix
JP5718573B2 (ja)	2015-05-13	トコフェロールの使用
US6794464B2 (en)	2004-09-21	Membrane or matrix for controlling the permeation rate of drugs
US6887948B2 (en)	2005-05-03	Method for preparing a siloxane-based elastomer composition
MXPA00012749A (en)	2001-07-31	A membrane or matrix for controlling the permeation rate of drugs
CN101583653B (zh)	2014-01-08	生育酚的应用